- Home
- FLGC vs SABS Comparison
FLGC vs SABS Comparison
Compare FLGC & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- SABS
- Stock Information
- Founded
- FLGC 2019
- SABS 2014
- Country
- FLGC United States
- SABS United States
- Employees
- FLGC N/A
- SABS N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- FLGC Health Care
- SABS Health Care
- Exchange
- FLGC Nasdaq
- SABS Nasdaq
- Market Cap
- FLGC 15.9M
- SABS 15.8M
- IPO Year
- FLGC 2021
- SABS N/A
- Fundamental
- Price
- FLGC $0.69
- SABS $2.64
- Analyst Decision
- FLGC Buy
- SABS Strong Buy
- Analyst Count
- FLGC 2
- SABS 5
- Target Price
- FLGC $4.00
- SABS $11.80
- AVG Volume (30 Days)
- FLGC 104.1K
- SABS 35.4K
- Earning Date
- FLGC 08-11-2025
- SABS 08-07-2025
- Dividend Yield
- FLGC N/A
- SABS N/A
- EPS Growth
- FLGC N/A
- SABS N/A
- EPS
- FLGC N/A
- SABS N/A
- Revenue
- FLGC $53,260,000.00
- SABS $377,835.00
- Revenue This Year
- FLGC N/A
- SABS N/A
- Revenue Next Year
- FLGC N/A
- SABS N/A
- P/E Ratio
- FLGC N/A
- SABS N/A
- Revenue Growth
- FLGC N/A
- SABS N/A
- 52 Week Low
- FLGC $0.42
- SABS $1.00
- 52 Week High
- FLGC $2.11
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- FLGC 55.93
- SABS 77.22
- Support Level
- FLGC $0.62
- SABS $1.72
- Resistance Level
- FLGC $0.72
- SABS $2.72
- Average True Range (ATR)
- FLGC 0.05
- SABS 0.19
- MACD
- FLGC 0.00
- SABS 0.10
- Stochastic Oscillator
- FLGC 75.00
- SABS 91.89
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.